RAPH Raphael Pharmaceutical Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1415397 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY33.4%
TTM EPS YoY-37.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-5,297.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27,028.6%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio-5,216.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $631,000 | $776,000 | $569,000 | $1.18M | $776,000 |
| SG&A expense | $614,000 | $733,000 | $763,000 | $2.14M | $853,000 |
| Operating income | -$1.25M | -$1.51M | -$1.33M | -$3.32M | -$1.63M |
| Net income | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.62M |
| EPS (basic) | 0.07 | 0.08 | 0.08 | 0.23 | 0.15 |
| EPS (diluted) | 0.07 | 0.08 | 0.08 | 0.23 | 0.15 |
| Weighted avg. shares (diluted) | 19.55M | 18.67M | 16.72M | 14.34M | 11.17M |
| Balance sheet | |||||
| Cash & equivalents | $45,000 | $19,000 | $230,000 | $288,000 | $153,000 |
| Receivables | $2,000 | $2,000 | — | — | — |
| Current assets | $51,000 | $25,000 | $237,000 | $331,000 | $422,000 |
| PP&E, net | $2,000 | $2,000 | $2,000 | — | — |
| Intangibles | — | — | $2,000 | $2,000 | — |
| Total assets | $53,000 | $27,000 | $239,000 | $333,000 | $422,000 |
| Current liabilities | $1.49M | $769,000 | $132,000 | $227,000 | $294,000 |
| Short-term debt | — | $41,000 | — | — | — |
| Total liabilities | $1.49M | $769,000 | $132,000 | $227,000 | $294,000 |
| Shareholders' equity | -$1.43M | -$742,000 | $107,000 | $106,000 | $128,000 |
| Shares outstanding | 20.18M | 18.70M | 18.50M | 15.62M | 12.97M |
| Cash flow statement | |||||
| Operating cash flow | -$210,000 | -$532,000 | -$1.20M | -$759,000 | -$1.42M |
| Capital expenditure | — | — | — | $2,000 | — |
| Free cash flow | — | — | — | -$761,000 | — |
| Investing cash flow | — | — | — | -$2,000 | — |
| Financing cash flow | $236,000 | $321,000 | $1.15M | $896,000 | $1.48M |
| Stock-based compensation | $245,000 | $350,000 | $200,000 | $2.29M | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.